Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL) (NCT06390956)

🧪 Interventions in This Study

• Pirtobrutinib (DRUG)
• Rituximab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (2 Sites)

• Washington University — St Louis, Missouri
• Huntsman Cancer Institute at University of Utah — Salt Lake City, Utah

📞 Contact the Study Coordinator

Phone: (801) 585-0115

Email: rachel.kingsford@hci.utah.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Marginal Zone Lymphoma

• A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma — Duarte, California
• Liso-Cel in Relapsed/Refractory Marginal Zone Lymphoma — Milwaukee, Wisconsin
• A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma — Washington D.C., District of Columbia
• Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma — Duarte, California
• Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) — Miami, Florida

Explore by condition: All Marginal Zone Lymphoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.